Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

ESMO open

Showing results (81-90 of 2,241) with videos related to

Pageof 225
Sort By:
ESMO Open|September 5, 2025
Toxicity and efficacy of antibody-drug conjugates in advanced solid tumors: a retrospective single-center analysis of clinical trialsR Woodford, H Almarzouq, N Beygozlu, et al.
ESMO Open|September 6, 2025
Phase I dose-escalation trial of AMXT 1501 dicaprate plus difluoromethylornithine: a dual-agent approach targeting immunosuppressive polyamine metabolismS A Piha-Paul, A W Tolcher, A L Vandross, et al.
ESMO Open|September 17, 2025
Letter to the editor re: CDX2 expression as a predictive and prognostic biomarker of 5-fluorouracil response in cancer of unknown primaryA Krämer
ESMO Open|August 29, 2025
Profiling autoantibodies at baseline and during immune checkpoint inhibitor therapy of renal cell carcinoma patients-exploratory results from TITAN-RCCA Fritzsch, K Leucht, N Röber, et al.
ESMO Open|May 23, 2021
The EMA assessment of avapritinib in the treatment of gastrointestinal stromal tumours harbouring the PDGFRA D842V mutationA Trullas-Jimeno, J Delgado, B Garcia-Ochoa, et al.
ESMO Open|May 13, 2021
SAUL, a single-arm study of atezolizumab for chemotherapy-pretreated locally advanced or metastatic carcinoma of the urinary tract: outcomes by key baseline factors, PD-L1 expression and prior platinum therapyA Bamias, A S Merseburger, Y Loriot, et al.
ESMO Open|May 13, 2021
Lack of prognostic impact of sentinel node micro-metastases in endocrine receptor-positive early breast cancer: results from a large multicenter cohort<sup>☆</sup>G Houvenaeghel, A de Nonneville, M Cohen, et al.
ESMO Open|May 13, 2021
A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CJLSG1903K Ito, M Morise, K Wakuda, et al.
ESMO Open|August 9, 2021
Sustained response to brigatinib in a patient with refractory metastatic pheochromocytoma harboring R1192P anaplastic lymphoma kinase mutation: a case report from the Austrian Group Medical Tumor Therapy next-generation sequencing registry and discussion of the literatureR Heregger, F Huemer, G Hutarew, et al.
ESMO Open|August 9, 2021
Quality of life with first-line pembrolizumab for PD-L1-positive advanced gastric/gastroesophageal junction adenocarcinoma: results from the randomised phase III KEYNOTE-062 studyE Van Cutsem, A Valderrama, Y-J Bang, et al.
Pageof 225

Showing results (81-90 of 2,241) with videos related to

Sort By:
Pageof 225
ESMO Open|September 5, 2025
Toxicity and efficacy of antibody-drug conjugates in advanced solid tumors: a retrospective single-center analysis of clinical trialsR Woodford, H Almarzouq, N Beygozlu, et al.
ESMO Open|September 6, 2025
Phase I dose-escalation trial of AMXT 1501 dicaprate plus difluoromethylornithine: a dual-agent approach targeting immunosuppressive polyamine metabolismS A Piha-Paul, A W Tolcher, A L Vandross, et al.
ESMO Open|September 17, 2025
Letter to the editor re: CDX2 expression as a predictive and prognostic biomarker of 5-fluorouracil response in cancer of unknown primaryA Krämer
ESMO Open|August 29, 2025
Profiling autoantibodies at baseline and during immune checkpoint inhibitor therapy of renal cell carcinoma patients-exploratory results from TITAN-RCCA Fritzsch, K Leucht, N Röber, et al.
ESMO Open|May 23, 2021
The EMA assessment of avapritinib in the treatment of gastrointestinal stromal tumours harbouring the PDGFRA D842V mutationA Trullas-Jimeno, J Delgado, B Garcia-Ochoa, et al.
ESMO Open|May 13, 2021
SAUL, a single-arm study of atezolizumab for chemotherapy-pretreated locally advanced or metastatic carcinoma of the urinary tract: outcomes by key baseline factors, PD-L1 expression and prior platinum therapyA Bamias, A S Merseburger, Y Loriot, et al.
ESMO Open|May 13, 2021
Lack of prognostic impact of sentinel node micro-metastases in endocrine receptor-positive early breast cancer: results from a large multicenter cohort<sup>☆</sup>G Houvenaeghel, A de Nonneville, M Cohen, et al.
ESMO Open|May 13, 2021
A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CJLSG1903K Ito, M Morise, K Wakuda, et al.
ESMO Open|August 9, 2021
Sustained response to brigatinib in a patient with refractory metastatic pheochromocytoma harboring R1192P anaplastic lymphoma kinase mutation: a case report from the Austrian Group Medical Tumor Therapy next-generation sequencing registry and discussion of the literatureR Heregger, F Huemer, G Hutarew, et al.
ESMO Open|August 9, 2021
Quality of life with first-line pembrolizumab for PD-L1-positive advanced gastric/gastroesophageal junction adenocarcinoma: results from the randomised phase III KEYNOTE-062 studyE Van Cutsem, A Valderrama, Y-J Bang, et al.
Pageof 225